DENVER, Colo., Feb 04, 2025 (247marketnews.com)- Quantum BioPharma (NASDAQ:QNTM) announced the completion of a double-blind, randomized, placebo-controlled clinical trial evaluating its dietary supplement, unbuzzd, on alcohol intoxication and metabolism. The results showed that unbuzzd significantly accelerated the reduction of blood alcohol concentration (BAC), reducing it over 40% faster within 30 minutes compared to a placebo.
Trial participants reported improvements in alertness and reduced perceived impairment. furthermore, and lessened hangover symptoms, including a 67% reduction in headache severity.
Dr. Andrzej Chruscinski, Quantum’s VP of Clinical and Scientific Affairs, stated, “We are thrilled to see such significant and meaningful outcomes in this clinical study. This study confirms the exceptional overall performance of unbuzzd to help reduce the acute effects of alcohol intoxication. We are also pleased to see that there were no product-related side effects or safety concerns in this clinical study.”
unbuzzd was reported to be well-tolerated with no adverse effects reported. It also helped stabilize heart rate and blood pressure, which are typically affected by alcohol intoxication. The formula, licensed to Celly Nutrition Corp., is available for purchase and aims to aid responsible alcohol consumption by speeding BAC reduction and alleviating the effects of intoxication and hangovers.
Zeeshan Saeed, Quantum’s CEO, added, “This clinical trial shows that unbuzzd is an important addition to the safe and responsible consumption of alcohol. Consumers now have the benefit of knowing that unbuzzd can reduce alcohol intoxication, speed the reduction of blood alcohol concentration, restore mental alertness and well-being, and help them avoid the worst symptoms of a hangover.”
The global hangover cure products market was expected to reach approximately $1.56 billion in 2024, offering a significant market opportunity. unbuzzd stands out with its clinically proven efficacy, which sets it apart from competitors that often lack strong clinical validation. The product’s rapid onset of action and its ability to provide comprehensive symptom relief, including faster BAC reduction and alleviation of hangover symptoms, address key consumer pain points. This combination of speed and effectiveness gives unbuzzd a competitive edge in the growing hangover remedy market.
The post Quantum Biopharma Reports unbuzzd Clinical Trial Success appeared first on 24/7 MarketNews.